Global Variation in Opioid Use in Prostate Cancer Trials.

Importance Regional variation in opioid use may be attenuated when pharmaceutical-sponsored trials include care that is often standardized by protocols. Understanding such variation is important for global trials that sometimes include time to opioid use as an end point. Objective To identify whether regional and country-level variation in opioid use exists among prostate cancer clinical trials across the world. Design, Setting, and Participants International phase 3 randomized clinical trials with patients with metastatic prostate cancer and initiation from January 1, 2008, or later were identified through internal databases of the US Food and Drug Administration. Data of patients in the intention-to-treat population from each trial were pooled. Descriptive and regression analyses of the collected data were conducted from September 2018 to February 2019. Exposures Cancer therapy. Main Outcomes and Measures Opioid use data were from concomitant medications reported in the database for each trial. Logistic regression models, descriptive statistics, and χ2 tests were used to compare opioid use across world regions while adjusting for patient age, presence of visceral disease, bony disease, and baseline Eastern Cooperative Oncology Group Performance Status score and pain score. Results In total, 9670 patients (mean [SD] age of 69.2 [8.3] years) from 8 prostate cancer clinical trials in 46 countries were included. Patients in Eastern Europe (adjusted odds ratio [AOR], 0.19; 95% CI, 0.16-0.22) and Asia (AOR, 0.31; 95% CI, 0.25-0.38) were less likely to use opioids compared with patients in North America. These findings held even when the analysis was restricted to patients who reported moderate to high pain levels at baseline (Eastern Europe: AOR, 0.16 [95% CI, 0.12-0.22]; Asia: AOR, 0.47 [95% CI, 0.29-0.79]). Within North America, rates of opioid use were similar between the United States and Canada (AOR, 1.13; 95% CI, 0.93-1.37). Conclusions and Relevance This study found that, despite the clinical trial setting, opioid use appeared to vary by world regions, suggesting that this variability should be considered in international clinical trials.

[1]  M. Hjermstad,et al.  Changes in medication use in a cohort of patients with advanced cancer: The international multicentre prospective European Palliative Care Cancer Symptom study , 2018, Palliative medicine.

[2]  Diane D. Liu,et al.  Opioid Prescription Trends Among Patients With Cancer Referred to Outpatient Palliative Care Over a 6-Year Period. , 2017, Journal of oncology practice.

[3]  Richard Pazdur,et al.  Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[5]  Ian R White,et al.  Should multiple imputation be the method of choice for handling missing data in randomized trials? , 2016, Statistical methods in medical research.

[6]  A. Abernethy,et al.  Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science , 2016, Prostate Cancer and Prostatic Diseases.

[7]  M. Bennett,et al.  Cancer induced bone pain , 2015, BMJ : British Medical Journal.

[8]  J. Cleary,et al.  An Examination of Global and Regional Opioid Consumption Trends 1980–2011 , 2014, Journal of pain & palliative care pharmacotherapy.

[9]  P. Kantoff,et al.  Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T , 2014, Prostate Cancer and Prostatic Disease.

[10]  B. Duthey,et al.  Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. , 2014, Journal of pain and symptom management.

[11]  L. Radbruch,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Radbruch,et al.  The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  L. Radbruch,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Radbruch,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Crowley,et al.  Patient income level and cancer clinical trial participation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Seya,et al.  A First Comparison Between the Consumption of and the Need for Opioid Analgesics at Country, Regional, and Global Levels , 2011, Journal of pain & palliative care pharmacotherapy.

[17]  L. Radbruch,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Deandrea,et al.  Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group , 2009, British Journal of Cancer.

[19]  W. Hohenberger,et al.  Differences Between Clinical Trial Participants and Patients in a Population-Based Registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry , 2009, Diseases of the colon and rectum.

[20]  S. Deandrea,et al.  Prevalence of undertreatment in cancer pain. A review of published literature. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Rachel P. Riechelmann,et al.  Symptom and medication profiles among cancer patients attending a palliative care clinic , 2007, Supportive Care in Cancer.

[22]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[23]  Aaditya Mattoo,et al.  Trade in International Maritime Services: How Much Does Policy Matter? , 1999 .

[24]  S. Larson,et al.  Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Lynch,et al.  Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .

[26]  S. Ramsey,et al.  Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. , 2016, JAMA oncology.

[27]  A. Bleyer,et al.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[28]  J. Cleary,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Cleary,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  K. Foley,et al.  Cancer Pain Relief , 1995, Springer Netherlands.

[31]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.